Company intelligence
Jazz Pharmaceuticals
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with rare diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003, we maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs in rare disease. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.
Verified activity
Signals from Jazz Pharmaceuticals
7 published signals
Presence & Recognition
Jazz Pharmaceuticals was represented at the Latinos in Bio ERG Summit by Dr. Lucy Sánchez-Abreu, Dianna Moore, and Josue Samayoa, moderated by John A. Suriel.
Reported by Dr. Lucy Sánchez-Abreu
People
Jazz Pharmaceuticals appointed Pamela Lonzer as Senior Compliance Officer, Global R&D and Tech Ops.
Reported by Pamela Lonzer
Presence & Recognition
Jazz Pharmaceuticals participates in World Leukemia Day to raise awareness of leukemia symptoms and support patient organizations.
Reported by Jazz Pharmaceuticals
Customers & Market
Jazz Pharmaceuticals cured a child with leukemia, marking the company's role in helping families like the Reed family.
Reported by Chuck Reed III
Research & Knowledge
Jazz Pharmaceuticals is redefining the treatment of difficult-to-treat cancers by focusing on innovative areas of research like targeted therapy.
Reported by Jazz Pharmaceuticals
Research & Knowledge
Jazz Pharmaceuticals is advancing science to redefine standards of care for HER2-positive cancers like GEA.
Reported by Jazz Pharmaceuticals
Research & Knowledge
Jazz Pharmaceuticals announced positive combination survival results from the Phase 3 HERIZON-GEA-01 trial investigating its first-line treatment for adults with HER2+ advanced gastroesophageal adenocarcinoma.
Reported by Jazz Pharmaceuticals